PF-04455242
| Clinical data | |
|---|---|
| Other names | PF-4455242; PF04455242; PF4455242 |
| Routes of administration | Oral |
| Drug class | κ-Opioid receptor antagonist |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C21H28N2O2S |
| Molar mass | 372.53 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
PF-04455242 is an experimental κ-opioid receptor (KOR) antagonist which was under development by Pfizer for the treatment of bipolar depression but was never marketed. Its development was discontinued in early clinical trials. It is taken by mouth.